Your browser is no longer supported. Please, upgrade your browser.
JAZZ Jazz Pharmaceuticals Public Limited Company daily Stock Chart
Jazz Pharmaceuticals Public Limited Company
Index- P/E20.65 EPS (ttm)5.69 Insider Own2.70% Shs Outstand60.71M Perf Week-2.12%
Market Cap7.14B Forward P/E10.19 EPS next Y11.54 Insider Trans-3.93% Shs Float59.13M Perf Month-6.62%
Income356.10M PEG1.15 EPS next Q2.61 Inst Own92.00% Short Float3.85% Perf Quarter-23.07%
Sales1.40B P/S5.10 EPS this Y460.60% Inst Trans0.43% Short Ratio3.59 Perf Half Y-22.66%
Book/sh27.97 P/B4.20 EPS next Y15.93% ROA10.30% Target Price183.25 Perf Year-9.76%
Cash/sh15.09 P/C7.79 EPS next 5Y18.03% ROE22.00% 52W Range108.50 - 160.00 Perf YTD-16.36%
Dividend- P/FCF17.99 EPS past 5Y44.40% ROI13.80% 52W High-25.52% Beta1.30
Dividend %- Quick Ratio5.30 Sales past 5Y50.10% Gross Margin92.90% 52W Low9.83% ATR2.73
Employees920 Current Ratio5.40 Sales Q/Q14.20% Oper. Margin37.80% RSI (14)43.52 Volatility2.10% 2.17%
OptionableYes Debt/Eq0.70 EPS Q/Q28.90% Profit Margin25.50% Rel Volume0.98 Prev Close117.56
ShortableYes LT Debt/Eq0.67 EarningsNov 08 AMC Payout0.00% Avg Volume634.24K Price119.17
Recom1.80 SMA20-1.63% SMA50-4.21% SMA200-11.45% Volume462,187 Change1.37%
Aug-10-16Reiterated Mizuho Buy $195 → $185
Jul-19-16Reiterated Mizuho Buy $193 → $195
Jun-06-16Initiated Goldman Buy $196
May-11-16Upgrade Mizuho Neutral → Buy $137 → $193
May-11-16Reiterated UBS Buy $162 → $168
Apr-25-16Upgrade Sun Trust Rbsn Humphrey Neutral → Buy
Feb-24-16Reiterated Mizuho Neutral $140 → $124
Feb-19-16Initiated Wells Fargo Outperform
Nov-25-15Initiated Bernstein Mkt Perform
Nov-10-15Downgrade Mizuho Buy → Neutral $164 → $140
Oct-14-15Initiated Northland Capital Outperform $200
Oct-09-15Initiated Mizuho Buy
Jun-29-15Reiterated UBS Buy $190 → $210
May-26-15Reiterated Guggenheim Buy $210 → $220
Feb-25-15Reiterated Deutsche Bank Buy $176 → $185
Feb-20-15Initiated BMO Capital Markets Outperform $200
Nov-05-14Upgrade R. F. Lafferty Neutral → Buy $200
May-09-14Reiterated R. F. Lafferty Neutral $140 → $130
Apr-17-14Initiated Canaccord Genuity Buy $163
Mar-07-14Resumed Barclays Overweight $200
Oct-25-16 04:05PM  Jazz Pharmaceuticals to Report 2016 Third Quarter Financial Results on November 8, 2016 PR Newswire
Oct-24-16 01:35PM  Top 5 valuable Pharma stocks : October 24, 2016
Oct-20-16 10:52AM  3 Healthcare Stocks That Are Looking Cheap at Motley Fool
Oct-09-16 01:12PM  These Are US Hedge Funds Favorite European Stocks at Insider Monkey
Oct-04-16 09:12AM  Jazz Initiates Rolling NDA for Leukemia Candidate Vyxeos
Oct-03-16 08:30AM  Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 2017 PR Newswire
Sep-28-16 10:05AM  Jazz Pharma Closes Enrollment in OSA Drug Phase III Trial
Sep-27-16 01:30PM  Goldman Sachs: Pharma Stocks That Need Price Hikes to Thrive Better Find a New Strategy Fast at
11:23AM  The Drug Price Increase Debate: Separating The Winners From The Losers
Sep-26-16 04:25PM  3 Top Biotech Stocks to Buy on Sale at Motley Fool
04:05PM  Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea PR Newswire
Sep-23-16 09:07AM  The Cheapest Stocks in Biotech at Motley Fool
Sep-21-16 01:04PM  Next Year Setting Up To Be Smooth For Jazz Pharmaceuticals
11:05AM  How Analysts See Horizon Compared to Its Peers
Sep-19-16 12:59PM  Understanding Valeants Improved Valuation Multiple
Sep-10-16 12:09PM  3 Mid-Cap Healthcare Stocks You Can Buy Right Now at Motley Fool
Sep-08-16 06:53PM  Halvorsen Bought 13 New Holdings in 2nd Quarter
Sep-07-16 04:05PM  Jazz Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference PR Newswire
Sep-06-16 04:00PM  3 Hottest Cancer Biotech Acquisition Targets After Medivation at Forbes
Aug-29-16 08:32AM  Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?
Aug-27-16 06:36PM  Here Are All The Big Biotech Mergers In 2016
Aug-26-16 09:05AM  Hedge Funds Are Obesely Overweight These 5 Mid-caps at Insider Monkey
Aug-25-16 03:52PM  Janney Initiates Jazz Pharma At Neutral, Cites Potential Competition For 'Blockbuster Narcolepsy Franchise'
Aug-24-16 12:03PM  ETFs with exposure to Jazz Pharmaceuticals Plc : August 24, 2016
Aug-23-16 09:04AM  Pfizers Medivation Acquisition: What You Need to Know
Aug-18-16 01:04PM  JAZZ PHARMACEUTICALS PLC Financials
Aug-16-16 08:18AM  4 Top Biotech Stocks That Can Be Purchased on the Cheap This Summer at Motley Fool
Aug-12-16 02:29PM  ETFs with exposure to Jazz Pharmaceuticals Plc : August 12, 2016
08:25AM  Why This Analyst Sees Huge Upside for Valeant and 2 More Specialty Pharmas at 24/7 Wall St.
Aug-11-16 03:04PM  Jazz Pharmaceuticals Remains A Buy At Deutsche Bank Post Q2 Report
10:06AM  Jazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
08:08AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : August 11, 2016
Aug-10-16 03:37PM  Jazz Pharmaceuticals (JAZZ) Stock Tumbles on Q2 Miss, Guidance -6.67%
10:28AM  Jazz Pharmaceuticals Remains On Goldman's Buy List
07:55AM  Jazz (JAZZ) Q2 Earnings Up Y/Y, Lowers Earnings Outlook
Aug-09-16 11:50PM  Edited Transcript of JAZZ earnings conference call or presentation 9-Aug-16 8:30pm GMT
06:11PM  Jazz misses Street 2Q forecasts
04:22PM  Jazz Pharmaceuticals Misses Earnings, Cuts Guidance
04:12PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Jazz Pharmaceuticals Announces Second Quarter 2016 Financial Results PR Newswire
07:07AM  Q2 2016 Jazz Pharmaceuticals PLC Earnings Release - After Market Close
Aug-06-16 08:53AM  4 Specialty Drugmakers Reporting Earnings Next Week
Aug-05-16 07:45AM  Jazz (JAZZ) Q2 Earnings: Will the Stock Disappoint?
Aug-02-16 07:15PM  CMS Grants New Technology Add-On Payment to Defitelio for the Treatment of Hepatic Veno-Occlusive Disease with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation PR Newswire
Jul-29-16 03:27PM  Jazz Financing I Ltd. -- Moody's: Xyrem Patent Loss Is Credit Negative, but Other Patents Still Exist; Ratings Unaffected at Moody's
08:05AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : July 29, 2016
Jul-28-16 04:05PM  Jazz Pharmaceuticals and Pfenex Enter into a Worldwide License and Option Agreement Related to Product Candidates in Early Development for Hematological Malignancies PR Newswire +7.69%
06:18AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events
Jul-27-16 11:49AM  Actinium Pharmaceuticals: Another Promising Name In The AML Space
Jul-25-16 04:05PM  Jazz Pharmaceuticals to Report 2016 Second Quarter Financial Results on August 9, 2016 PR Newswire
Jul-22-16 12:05PM  What Is An Options Sweep?
Jul-18-16 01:03PM  This Could Be the Next Big Pharma Buyout at Motley Fool
Jul-17-16 01:59PM  Forget the Me-Too Cancer Drugs -- These Breakthroughs Are Where You Want to Invest at Motley Fool
Jul-15-16 09:17AM  Bulls Crowd Into Jazz Pharmaceuticals For Good Reason at Forbes
09:06AM  Jazz Pharmaceuticals: How Much Return Potential Does It Have?
Jul-14-16 01:11PM  Ligand Pharmaceuticalss Performance Based on EV-to-EBITDA
01:11PM  Understanding Ligand Pharmaceuticalss PE Multiple
11:08AM  A Look at Celators Lead Drug Vyxeos
10:06AM  How Can Celators Portfolio Complement Jazz Pharmaceuticals?
Jul-13-16 03:51PM  A Look at Jazz Pharmaceuticals Celator Acquisition Deal
03:51PM  Why Did Jazz Fall after Celator Acquisition Announcement?
01:16PM  Jazz Financing I Ltd. -- Moody's: Jazz's Upsized revolving credit facility is positive for liquidity; ratings unaffected at Moody's
Jul-12-16 04:04PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a Direct
01:50AM  Jazz Pharmaceuticals plc Announces Results of Tender Offer to Purchase All of The Outstanding Shares of Common Stock of Celator Pharmaceuticals, Inc. PR Newswire
Jun-29-16 04:25PM  Jazz Pharma (JAZZ) Stock Receives 'Outperform' Rating at BMO Capital
Jun-27-16 08:21AM  Why Celator Pharmaceuticals Is Up 1,610% in 2016 at Motley Fool
12:09AM  Jazz Pharmaceuticals Announces Expiration of HSR Waiting Period for Proposed Celator Pharmaceuticals, Inc. Acquisition PR Newswire
Jun-23-16 06:55AM  Five companies that could buy Ariad this year for as much as $2.9B at
Jun-20-16 04:30PM  Jazz Pharmaceuticals PLC Conference Call to Discuss On JZP-110 Investor Update scheduled for 4:30 pm ET today
03:37PM  Jazz Pharmaceuticals Plc Value Analysis (NASDAQ:JAZZ) : June 20, 2016
Jun-15-16 09:42AM  Jazz Pharmaceuticals Offers HAL Study Data on JZP-110
08:03AM  4 Cancer Drug Developers You Need to Have on Your Radar This Year at Motley Fool
Jun-14-16 04:05PM  Jazz Pharmaceuticals Announces Conference Call and Webcast for JZP-110 Investor Update PR Newswire
09:05AM  Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability (HAL) Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting PR Newswire
08:34AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : JAZZ-US : June 14, 2016
Jun-10-16 06:42PM  5 Appealing Biotechnology Stocks for Healthy Long-term Returns
Jun-06-16 04:43PM  Jazz Pharma Started At Buy; Visa And Wal-Mart Upgraded
10:14AM  Specialty Pharma: After the M&A Fueled Super Cycle at
10:01AM  3 Cheap Biotech Stocks You Can Buy Now at Motley Fool
07:29AM  Coverage initiated on Jazz Pharma by Goldman
Jun-04-16 09:40AM  Why Celator Pharmaceuticals Shares Skyrocketed 100% in May at Motley Fool
Jun-03-16 06:21PM  Celator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders PR Newswire
01:29PM  Sarepta Therapeutics: Bears are 'Fundamentally Wrong.' Here's Why. at
09:46AM  The market is looking for a Celator spoiler bid
Jun-02-16 09:03AM  3 Incredibly Cheap Biotech Stocks at Motley Fool
Jun-01-16 01:17PM  Yes, Biotech Unicorns Are Still Real at Bloomberg
11:15AM  8 Mergers You Might Have Missed On Tuesday
10:55AM  CPXX: Jazz Acquires Celator for $30.25 per Share
07:30AM  [$$] Venture Investors in Celator Pharma Rewarded for Taking the Long View at The Wall Street Journal
06:07AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits
May-31-16 05:20PM  Top Trades: Biotech bottom in?
04:36PM  Jazz Pharma Paying 4 Times Peak Sales For Celator Leukemia Drug
03:29PM  Stocks on Track for Mixed May as Dow Loses Gains
12:22PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Celator Pharmaceuticals, Inc. to Jazz Pharmaceuticals plc - CPXX Accesswire
12:14PM  Why Celator Pharmaceuticals, Cliffs Natural Resources and 3 Other Stocks are Flying High Today at Insider Monkey
11:30AM  Here's Why Shares of Celator Are Climbing on Tuesday at TheStreet
11:14AM  A bunch of hedge funds are cashing in big on the Celator drug deal
11:09AM  Stocks Waver as Boost in Spending Lifts Rate Hike Chances
11:06AM  Why Celator Pharmaceuticals Shares Are Skyrocketing Today at Motley Fool
10:32AM  Jazz Pharmaceuticals buying Celator for $1.5B at USA TODAY
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, a late-stage investigational compound, which is in phase III clinical trail for the treatment of EDS in narcolepsy and obstructive sleep apnea; and JZP-386, a deuterium-modified analog of sodium oxybate that is completed phase I clinical trail for use in patients with narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLER MICHAEL PATRICKSVP, US CommercialOct 17Sale118.1620023,63217,125Oct 18 05:14 PM
MILLER MICHAEL PATRICKSVP, US CommercialSep 19Sale126.1720025,23417,325Sep 20 05:34 PM
Mulligan SeamusDirectorAug 25Sale128.3227,9683,588,7871,048,008Aug 26 04:24 PM
Treacy PaulSVP, Technical OperationsAug 16Sale137.471,292177,60913,870Aug 18 04:47 PM
MILLER MICHAEL PATRICKSVP, US CommercialAug 15Sale136.4510013,64517,525Aug 16 06:42 PM
Winningham Rick EDirectorAug 15Sale136.4563386,37315,391Aug 17 05:47 PM
Sohn Catherine A.DirectorAug 15Sale136.4563386,3736,116Aug 17 05:41 PM
RIEDEL NORBERT GDirectorAug 15Sale136.4563386,3734,953Aug 17 05:35 PM
McSharry Heather AnnDirectorAug 15Sale136.4568593,4686,076Aug 17 05:31 PM
ENRIGHT PATRICK GDirectorAug 15Sale136.4563386,3732,042Aug 17 05:25 PM
BERNS PAUL LDirectorAug 15Sale136.4563386,3735,234Aug 17 05:20 PM
Smith Karen L.Global Head of R&D and CMOAug 12Buy137.1060883,35614,182Aug 12 04:36 PM
Cox Russell J.EVP & COOAug 09Sale148.664,000594,64051,038Aug 10 04:39 PM
COZADD BRUCE CChairman & CEOAug 09Sale150.001,000150,000299,184Aug 11 04:49 PM
MILLER MICHAEL PATRICKSVP, US CommercialJul 15Sale142.4310014,24317,625Jul 18 07:55 PM
Smith Karen L.Global Head of R&D and CMOJul 13Buy143.6358083,30513,574Jul 13 08:09 PM
MILLER MICHAEL PATRICKSVP, US CommercialJun 15Sale149.6410014,96417,725Jun 16 05:33 PM
Smith Karen L.Global Head of R&D and CMOJun 13Buy149.6155783,33512,994Jun 15 05:17 PM
Mulligan SeamusDirectorMay 24Sale150.2927,9684,203,3391,074,611May 26 05:02 PM
MILLER MICHAEL PATRICKSVP, US CommercialMay 16Sale145.2010014,52017,753May 17 05:56 PM
RIEDEL NORBERT GDirectorMay 16Sale145.2064493,5094,221May 17 05:39 PM
McSharry Heather AnnDirectorMay 16Sale145.20697101,2045,396May 17 05:31 PM
WILSON KAREN JSVP, Finance & PAOApr 25Sale160.0060496,64018,059Apr 27 06:15 PM
MILLER MICHAEL PATRICKSVP, US CommercialApr 15Sale145.7910014,57918,792Apr 18 05:04 PM
Cox Russell J.EVP & COOApr 12Sale136.984,000547,92060,470Apr 13 04:29 PM
WILSON KAREN JSVP, Finance & PAOApr 07Sale140.902,161304,48523,670Apr 08 04:43 PM
MILLER MICHAEL PATRICKSVP, US CommercialMar 15Sale129.1710012,91718,892Mar 16 05:48 PM
COZADD BRUCE CChairman & CEOMar 08Sale126.042,500315,100300,066Mar 09 07:26 PM
Treacy PaulSVP, Technical OperationsFeb 29Sale123.4835443,71215,100Mar 02 05:59 PM
Mulligan SeamusDirectorFeb 23Sale122.7127,9683,431,9041,102,579Feb 24 07:56 PM
COZADD BRUCE CChairman & CEOFeb 09Sale111.372,500278,425281,896Feb 11 05:01 PM
MILLER MICHAEL PATRICKSVP, US CommercialJan 15Sale122.6610012,26613,561Jan 21 11:43 AM
COZADD BRUCE CChairman & CEOJan 12Sale123.812,500309,525284,396Jan 14 06:52 PM
ENRIGHT PATRICK GDirectorJan 05Sale138.0910,0001,380,8904,519Jan 07 04:46 PM
MILLER MICHAEL PATRICKSVP, US CommercialDec 15Sale136.9910013,69913,661Dec 17 04:11 PM
ENRIGHT PATRICK GDirectorDec 02Sale148.4942462,9601,310Dec 03 04:29 PM
ENRIGHT PATRICK GDirectorDec 01Sale146.5910,0001,465,9104,716Dec 03 04:29 PM
Mulligan SeamusDirectorNov 23Sale147.9010,2431,514,9281,130,547Nov 24 06:50 PM
Mulligan SeamusDirectorNov 20Sale144.6817,7252,564,3681,140,790Nov 24 06:50 PM
MILLER MICHAEL PATRICKSVP, US CommercialNov 16Sale134.0310013,40313,690Nov 17 08:47 PM
McGill IainSVP, Europe & Rest of WorldNov 13Sale135.672,821382,73719,146Nov 17 05:24 PM
COZADD BRUCE CChairman & CEONov 10Sale128.532,500321,325289,355Nov 12 07:19 PM
ENRIGHT PATRICK GDirectorNov 10Sale135.2910,0001,352,8624,912Nov 12 04:25 PM